1 / 6

Retinal Degeneration Pipeline Therapeutics Assessment H1 201

This report gives thorough data on the helpful advancement for Retinal Degeneration, complete with near examination at different stages, therapeutics appraisal by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort

Ctroutman01
Download Presentation

Retinal Degeneration Pipeline Therapeutics Assessment H1 201

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Retinal Degeneration - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 29-May-2015 No. of pages: 82 Single User License: US $2000 Browse more Reports on Ophthalmology Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Retinal Degeneration - Pipeline Review, H1 2015 This report gives thorough data on the helpful advancement for Retinal Degeneration, complete with near examination at different stages, therapeutics appraisal by medication target, instrument of activity (MoA), course of organization (RoA) and particle sort, alongside most recent upgrades, and included news and press discharges. It likewise surveys key players included in the remedial improvement for Retinal Degeneration and unique components on late-stage and stopped undertakings. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Retinal Degeneration - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : Alkeus Pharmaceuticals, Inc., Applied Genetic Technologies Corporation, Aprogen, Inc., BBB Therapeutics B.V., Bionature E.A. Ltd., Biovista Inc., GenSight Biologics SA, SanBio, Inc., Santhera Pharmaceuticals Holding AG, Senju Pharmaceutical Co., Ltd. and Spark Therapeutics, Inc. Drugs Profile Discussed in this Research : AP-202, BVA-202, BVA-203, CB-11, Drug for Lebers Hereditary Optic Neuropathy, Gene Therapy for Choroideremia, Gene Therapy for Retinal Degenerative Disease, Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis, GS-010, idebenone, MTP-131, rAAV2tYFCB-hRS1, SB-623 and some more. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Retinal Degeneration - Pipeline Review, H1 2015 Scope For Retinal Degeneration - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Retinal Degeneration - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Retinal Degeneration - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related